跳至主要内容
临床试验/NCT03540498
NCT03540498已完成不适用

Oral Colonization by Lactobacillus Brevis KABP 052 (CECT 7480) and Lactobacillus Plantarum KABP 051 (CECT 7481): A Randomized, Double-Blinded, Placebo-Controlled Trial

AB Biotics, SA0 个研究点目标入组 40 人开始时间: 2016年10月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
40
主要终点
Probiotic colonization of the oral cavity (qPCR)

研究概览

简要总结

Study will follow a randomized, double-blind, placebo-controlled design with two groups in parallel,N of 40 patients in 6 weeks of follow up for the evaluation of two different posology models (daily consumption of probiotic gum, with or without previous professional oral cleaning). Probiotics have recently been used to combat oral diseases (plaque control, caries, halitosis, etc.), as a non-invasive natural therapy.

详细描述

The study will follow a randomized, double-blind, placebo-controlled design with two groups in parallel, for the evaluation of two different posology models (daily consumption of probiotic gum, with or without previous professional oral cleaning). Probiotics have recently been used to combat oral diseases (plaque control, caries, halitosis, etc.), as a non-invasive natural therapy.

The aim of this study is to assess whether the daily consumption of AB-DENTALAC gum allows the colonization of strains L.plantarum KABP051 (CECT7481) and L.brevis KABP052 (CECT7480) in the oral microbiota, and to confirm the absence of side effects, with the following setup:

  1. Number of patients to be randomized:40
  2. Number of visits per patient: 2

The study will determine the index of plaque and gingival index as a measure of oral health. The presence of Lactobacillus in the samples collected by qPCR will also be quantified.

The patient will benefit from a buccal revision and control by a periodontist for 6 weeks. It will also help subsequent patients to obtain a better treatment (if the results are significant). No harm is expected to participate, it is a minimal risk study, with non-invasive exploratory tests and a product suitable for human consumption and marketed in Europe since 2012.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

盲法说明

Once the patients have been selected according to the inclusion / exclusion criteria detailed below, they will be included in one of the treatment groups (control / study) in a random and random manner. The list of randomization and the labeling of the products will be carried out by independent personnel to the research team to ensure double blindness of the trial. The production of the probiotic products and control will be carried out in both cases in white boxes without any type of identification or difference between them.

The randomization will be made from an online software available at www.randomization.com. From the list of randomization generated by this software, the different products will be labeled with the patient number and the test code. The team of researchers will not have access to the randomization list. In this way, a correct randomization and double-blind trial is guaranteed.

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Women and men between 18-55 years.
  • Capacity to understand the procedures and implications of the study.
  • Gingival Index <1,5 (Löe and Silness, Acta Odontol Scand.
  • Plaque Index <2,0 (Löe and Silness, Acta Odontol Scand.
  • Periodontal pocket depth <5 mm

排除标准

  • Less than 20 natural teeth
  • More than 2 untreated caries at the time of enrollment
  • Current orthodontic or periodontal treatment
  • Hypersensitivity or allergy to any of the ingredients of the experimental product
  • Consumption of antibiotics in the 8 weeks prior to treatment
  • Use of probiotics designed to improve oral health, or having consumed them during the 8 weeks prior to the study
  • Consumption of any type of probiotic during the 4 weeks prior to the study
  • Usual consumption of clorhexidine or other mouthwashes with bactericidal active ingredients during the 30 days before the start of the study
  • Pregnant or lactating women
  • Participants with chronic diseases (eg, diabetes, kidney problems, cancer) or under chronic treatment

结局指标

主要结局

Probiotic colonization of the oral cavity (qPCR)

时间窗: Change from Baseline assessed 6 weeks after study entry

Quantification of L. brevis and L. plantarum by species-specific qPCR in pooled samples of saliva, dental plaque (from the CPI subset) and lingual plaque

次要结局

  • Progression of GI(Change from Baseline assessed 6 weeks after study entry)
  • Progression of PII(Change from Baseline assessed 6 weeks after study entry)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验